Ariad Pharmaceuticals Inc fka ARIA

[DonShimoda]

Merrill's expectation of a 70%+ MCyR for T315I pts. after only 57 days was unrealistic to begin with. In the Phase 1 trial, 82% of CML CP pts with T315I mutation had CHR but that was after 142-599 days. My expectation is that the updated data available at the presentation will confirm the response rates are moving in the right direction.

Basically, yesterdays sell off seems to be a combination of unrealistic response rate expectations and a misreading of the SAE data. Typical knee jerk reaction by short term "investors" who don't bother to read more than just the headlines.